Get the Stockscreener App
32.18
5.38%
-1.83
After Hours:
31.95
-0.23
-0.71%
Tonix Pharmaceuticals Holding Corp stock is traded at $32.18, with a volume of 991.74K.
It is down -5.38% in the last 24 hours and down -35.28% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$34.01
Open:
$33.44
24h Volume:
991.74K
Relative Volume:
0.73
Market Cap:
$282.09M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-2.8579
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-10.74%
1M Performance:
-35.28%
6M Performance:
+293.40%
1Y Performance:
-11.42%
1-Day Range:
$32.03
$34.04
1-Week Range:
$32.03
$39.45
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
32.18 | 298.13M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Has Tonix Pharmaceuticals Holding Corp. found a price floorOptions Play & Free Community Supported Trade Ideas - Newser
Using economic indicators to assess Tonix Pharmaceuticals Holding Corp. potentialJuly 2025 Momentum & Free High Return Stock Watch Alerts - Newser
What technical models suggest about Tonix Pharmaceuticals Holding Corp.’s comeback2025 Top Gainers & Trade Opportunity Analysis - Newser
Will Tonix Pharmaceuticals Holding Corp. stock go up soonInsider Selling & Verified Entry Point Signals - Newser
How institutional ownership impacts Tonix Pharmaceuticals Holding Corp. stock2025 Momentum Check & Free Community Supported Trade Ideas - Newser
How to integrate Tonix Pharmaceuticals Holding Corp. into portfolio analysis toolsEarnings Summary Report & Weekly High Potential Stock Alerts - Newser
How to read the order book for Tonix Pharmaceuticals Holding Corp.Rate Hike & Technical Confirmation Trade Alerts - Newser
How to forecast Tonix Pharmaceuticals Holding Corp. trends using time series2025 Trading Volume Trends & Weekly High Return Stock Opportunities - Newser
Published on: 2025-08-27 01:33:58 - Newser
Is it too late to sell Tonix Pharmaceuticals Holding Corp.Bear Alert & Comprehensive Market Scan Reports - Newser
What earnings revisions data tells us about Tonix Pharmaceuticals Holding Corp.Earnings Summary Report & Community Driven Trade Alerts - Newser
Leading vs lagging indicators on Tonix Pharmaceuticals Holding Corp. performanceVolume Spike & Expert Curated Trade Setups - Newser
Using R and stats models for Tonix Pharmaceuticals Holding Corp. forecasting2025 Major Catalysts & Real-Time Sentiment Analysis - Newser
What MACD and RSI say about Tonix Pharmaceuticals Holding Corp.July 2025 Trends & Low Risk Profit Maximizing Plans - Newser
Will Tonix Pharmaceuticals Holding Corp. rebound enough to break even2025 Winners & Losers & AI Driven Stock Reports - Newser
Combining price and volume data for Tonix Pharmaceuticals Holding Corp.2025 Price Action Summary & Low Drawdown Trading Strategies - Newser
Analyzing recovery setups for Tonix Pharmaceuticals Holding Corp. investors2025 Analyst Calls & Weekly Watchlist of Top Performers - Newser
Published on: 2025-08-26 09:44:59 - Newser
Can momentum traders help lift Tonix Pharmaceuticals Holding Corp.Quarterly Risk Review & Weekly Stock Breakout Alerts - Newser
Can a trend reversal in Tonix Pharmaceuticals Holding Corp. lead to recoveryFed Meeting & Advanced Technical Analysis Signals - Newser
Using data models to predict Tonix Pharmaceuticals Holding Corp. stock movement2025 Major Catalysts & Fast Entry and Exit Trade Plans - Newser
Can Tonix Pharmaceuticals Holding Corp. hit a new high this monthMarket Sentiment Review & Long-Term Growth Plans - Newser
Heatmap Data Shows High Activity in Tonix Pharmaceuticals Holding Corp. SectorJuly 2025 Retail & Target Return Focused Picks - beatles.ru
Real time social sentiment graph for Tonix Pharmaceuticals Holding Corp.July 2025 Action & AI Enhanced Trading Alerts - Newser
Analyzing Tonix Pharmaceuticals Holding Corp. with multi timeframe charts2025 Risk Factors & Low Drawdown Momentum Ideas - Newser
Tools to assess Tonix Pharmaceuticals Holding Corp.’s risk profilePortfolio Return Summary & Real-Time Buy Signal Alerts - Newser
Tonix Ready To Revive Fibromyalgia Market With Tonmya - insights.citeline.com
SA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXP - Seeking Alpha
Tonix Pharmaceuticals shares fall 1.45% intraday as AbbVie acquires Capstan Therapeutics for $2.1 billion. - AInvest
Tonix Pharmaceuticals Reports Q2 2025 Financial Results - MSN
Tonix Bets On Fibromyalgia Approval To Revive Growth Ambitions - Finimize
Tonix Pharmaceuticals' Tonmya: A First-in-Class Win with Long-Term Growth Potential - AInvest
Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) - Seeking Alpha
Tonix receives FDA approval of Tonmya for treatment of fibromyalgia - Indian Pharma Post
Tonix Pharmaceutical’s Tonmya approved: first fibromyalgia drug in 15 years - Proactive Investors
Key resistance and support levels for Tonix Pharmaceuticals Holding Corp.July 2025 Gainers & Stepwise Trade Signal Implementation - Newser
First in 15 Years: Tonix Secures FDA Green Light for Tonmya in Fibromyalgia Treatment - geneonline.com
What moving averages say about Tonix Pharmaceuticals Holding Corp.July 2025 Update & Short-Term Swing Trade Alerts - Newser
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):